Axol Bioscience - May Newsletter

Welcome to the May edition of our Axol Bioscience newsletter! It's been another busy month in the iPSC industry and, with a host of global activities, events and exciting company updates, this month's theme has been supporting the global iPSC market.

• We reached a big milestone this month with 8000 followers on LinkedIn! A huge thank you to our supportive community who always provide useful feedback and engage with our content. If you haven't followed us yet, make sure to visit our page - we post data, updates and announcements several times a week!
• We travelled to Boston, MA for the Target ALS annual meeting to speak about our work unlocking iPSC technology for ALS , and then ventured closer to home with the Brain Health Life Sciences Summit at the University of St Andrews. We always enjoy the opportunity to discuss our industry-leading iPSC activity at conferences around the world, and we're looking forward to big upcoming events like MPS (see below for more information!)
• May has been a big month for global in vitro neurodegenerative disease research with Huntington's Disease Awareness Month, the publication of a landmark Nature paper on APOE4 in Alzheimer's Disease. As one of our key priorities, we're pleased to see increased emphasis on the use of advanced in vitro models to study Alzheimer's Disease, Huntington's Disease, ALS and other neurodegenerative diseases.

New product: the fastest and most affordable human iPSC-derived astrocytes on the market

We're delighted to announce our new axoCells? Astrocytes line (ax0704) designed to fuel robust in vitro models for neurodegenerative disease research and drug discovery. With many labs still using rat astrocytes for their work (with very long protocols, some even >100 days), we're "supporting the switch" to human iPSCs with this new axoCells Astrocytes product that can drive faster, cheaper in vitro workflows.

Key highlights of our new axoCells Astrocytes product include:

• Best price on the market: ￡660 / $830 / €770 per vial?(1 million cells)
• Derived from fibroblasts taken from a healthy 40-50-year-old male donor
• Assay ready in just 48 hours
• Express seven key markers of primary human astrocytes including GFAP, AQP4 and S100B and astrocyte-associated markers (EAAT1 and ALDH1L1) with low levels of neuronal progenitor markers including Nestin
• Specifically developed for use in powerful?in vitro?monoculture models and complex co-culture systems for drug discovery

Bolstered by our world-leading ISO 9001-accredited manufacturing processes, we are delighted to pass on further cost savings to you. Our new ax0704 astrocytes are cheaper than previous astrocytes and are priced at just ￡660 / $830 / €770 per vial (1 million cells)- the best price on the market!

Click here to read more about this new product line and how you can use axoCells Astrocytes to power robust, physiologically relevant models of Alzheimer’s Disease, Parkinson’s Disease and ALS: https://axolbio.com/new-product-launch-new-line-lower-price-axocellstm-astrocytes-for-better-neurodegenerative-disease-modeling/

Want to explore the details and get a quote? Click here: axoCells Astrocytes AXOL Bioscience

Explore our new axoCells Catalog

Looking to use high-quality iPSC-derived cells in your in vitro projects? Take a look at our new axoCells Catalog!

We've produced a comprehensive document to highlight our axoCells range, comprising human iPSC-derived cells optimized for use in advanced in vitro model systems for research, toxicity screening and drug discovery.

Explore our axoCells Catalog to discover:

• The cells in our key therapy areas: neuroscience, pain/inflammation and cardiovascular
• The multiple applications of our axoCells range including monoculture, co-culture, microfluidics and organ-on-chip devices
• Extensive characterization and functional validation data for each of our cell types
• Details behind our industry-leading quality standards including ISO 9001 and ISSCR compliance
• Information about the wider products (kits, reagents and supplements), ordering information and our Shipping and Logistics division

Take a look at the catalog here: https://axolbio.com/publications/2024-axocells-catalog/

We've also released several other documents outlining different aspects of our work, with great feedback from our customers around the world. If you'd like a quick summary of our mission, products, services and expertise then check out the 2024 Axol Bioscience Directory and our (more comprehensive) 2024 Axol Bioscience eBook . For the quality-focused among you there's our discussion document on functional QC while cardiac researchers will appreciate our 2024 Cardiac Guide . We've also got documents on ALS , TREM2 and our brand-new 2024 Axol Bioscience Product Brochure which we describe below.

It's official: Axol Bioscience is an Outstanding Workplace 2024

We're delighted to announce that Axol Bioscience has been awarded People Insight’s Outstanding Workplace Award 2024 highlighting our ongoing commitment to fostering a positive, productive workplace.

With a top-quartile score of 85% for employee engagement, this award celebrates our investment in employee engagement and the positive culture we are creating, centered around our core company values of Transparency, Accountability, Collaboration, Diversity & Inclusivity, Performance and Integrity.

Click to read more about this award: Axol Bioscience - Outstanding Workplace Award 2024

Axol adds LubioScience and Cambridge Bioscience to distributor network

We are excited to be working with LubioScience and Cambridge Bioscience to bring iPSC-derived cells and better models of human disease to customers in Switzerland and the UK respectively.

• As Switzerland's fastest growing Life Science distributor, we are looking forward to working with Lubio Science and seeing the increased impact our products have on neuroscience drug discovery and cardiovascular drug safety in Switzerland.
• Cambridge Bioscience are a leading UK-based Life Science distributor with over 30 years of experience,

They join our valued partners Koma Biotech (Korea) and Cosmo Bio (Japan) who are helping us to support the global iPSC industry with our high-quality products.

Click here to see our distribution partner list and stay tuned for more updates!

Meet us at BIO and MPS next month

In June, we're continuing our commitment to building relationships in the iPSC industry by attending conferences and events around the world. We'd like to draw your attention to two big events happening in the next few weeks:

• From the 3rd-6th June, our CEO Liam Taylor and CSO Ashley Barnes will be at BIO 2024 in San Diego discussing our work unlocking iPSC technology for global biopharma researchers
• From the 10th-14th June, we'll be in Seattle attending the MPS World Summit 2024 (Booth #101) to talk about our work powering MPS platforms with high-quality, functional human iPSC-derived cells

We will also be heading to the BTS Discovery Toxicology event and the BioBabraham Symposium - keep checking our LinkedIn page for more.

Make sure to speak to our team if you're attending! If you're not planning on going, get in touch at [email protected] to discuss how we can support your iPSC research.